$353 Million is the total value of Redmile Group, LLC's 51 reported holdings in Q3 2012. The portfolio turnover from Q2 2012 to Q3 2012 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q3 2012 |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2012-12-03
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 46 | Q2 2024 | 10.1% |
ATARA BIOTHERAPEUTICS INC | 38 | Q1 2024 | 6.4% |
FATE THERAPEUTICS INC | 37 | Q2 2024 | 17.2% |
INVITAE CORP | 33 | Q4 2023 | 2.7% |
REGENXBIO INC | 31 | Q2 2024 | 3.8% |
IMMUNOGEN INC | 28 | Q4 2023 | 17.4% |
CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
DECIPHERA PHARMACEUTICALS IN | 27 | Q1 2024 | 7.0% |
CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
FATE THERAPEUTICS INC | March 25, 2024 | 17,619,095 | 14.9% |
Science 37 Holdings, Inc.Sold out | March 13, 2024 | 0 | 0.0% |
Absci Corp | March 05, 2024 | 8,282,016 | 7.0% |
ADC Therapeutics SA | February 14, 2024 | 15,328,317 | 18.8% |
Akero Therapeutics, Inc. | February 14, 2024 | 1,109,476 | 2.0% |
ALX ONCOLOGY HOLDINGS INC | February 14, 2024 | 4,909,264 | 9.6% |
AMICUS THERAPEUTICS, INC. | February 14, 2024 | 21,957,926 | 7.3% |
Annexon, Inc. | February 14, 2024 | 8,083,776 | 9.9% |
Ayala Pharmaceuticals, Inc. | February 14, 2024 | 211,014 | 1.9% |
Deciphera Pharmaceuticals, Inc. | February 14, 2024 | 8,359,768 | 9.9% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G/A | 2024-09-13 |
N-PX | 2024-09-03 |
13F-HR | 2024-08-14 |
SC 13D/A | 2024-07-19 |
4 | 2024-07-03 |
4 | 2024-07-02 |
4 | 2024-06-21 |
4 | 2024-06-18 |
4 | 2024-06-14 |
4 | 2024-06-11 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.